Kythera Biopharmaceuticals' Drug Successfully Reduces Double Chin in Studies

Published: Sep 19, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Kythera Biopharmaceuticals Inc said its experimental injectable drug succeeded in reducing double chin of patients in late-stage studies, meeting the main and secondary goals of two clinical trials. The company's shares jumped 10 percent on the positive data for its lead drug, ATX-101. Over 1000 patients with moderate to severe submental fat were tested in the two studies conducted in the United States and Canada, where ATX-101 was evaluated against a placebo.

Help employers find you! Check out all the jobs and post your resume.

Back to news